MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive.

Patients with an early age of onset (AO) were also more likely to receive less effective first-line oral therapy than those with later AOs.

The FDA previously declined to approve de novo classification in April 2019.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.

The EDSS inaccurately reported improvement rates while paralleling disability progression rates.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

Individuals whose mothers had pregestational diabetes mellitus had a statistically significant 2.3-fold increased risk of developing multiple sclerosis.

Neurological disability, as assessed by EDSS, was also found to be associated with higher levels of MS fatigue.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

An analysis of MSBase data including more than 14,000 patients with MS suggests that disease-modifying therapies are effective in improving disability outcomes in relapsing disease.

Here's what is coming soon to NeurologyLive.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Leigh Charvet, PhD.

Catch up on the best and most listened to episodes of the NeurologyLive Mind Moments podcast, featuring exclusive interviews with experts in neurology.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD, and a number of others.